Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors

被引:15
|
作者
Powell, NA [1 ]
Clay, EH [1 ]
Holsworth, DD [1 ]
Bryant, JW [1 ]
Ryan, MJ [1 ]
Jalaie, M [1 ]
Edmunds, JJ [1 ]
机构
[1] Pfizer Global Res & Dev, Michigan Labs, Ann Arbor, MI 48105 USA
关键词
renin inhibitor; hypertension; topliss tree;
D O I
10.1016/j.bmcl.2005.07.063
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Inhibition of renin enzymatic activity by a series of ketopiperazine-based compounds containing a C6 benzyloxymethyl substituent correlated with a +(pi + sigma) effect. A 3-pyridinyloxymethyl substituent was also found to be equipotent as higher molecular weight analogs, and exhibited decreased CYP3A4 inhibition levels and improved pharmacokinetic properties. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4713 / 4716
页数:4
相关论文
共 50 条
  • [1] Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors
    Powell, NA
    Clay, EH
    Holsworth, DD
    Bryant, JW
    Ryan, MJ
    Jalaie, M
    Zhang, E
    Edmunds, JJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) : 2371 - 2374
  • [2] Ketopiperazine-based renin inhibitors: Optimization of the "C" ring
    Holsworth, DD
    Cai, CM
    Cheng, XM
    Cody, WL
    Downing, DM
    Erasga, N
    Lee, C
    Powell, NA
    Edmunds, JJ
    Stier, M
    Jalaie, M
    Zhang, EL
    McConnell, P
    Ryan, MJ
    Bryant, J
    Li, TS
    Kasani, A
    Hall, E
    Subedi, R
    Rahim, M
    Maiti, S
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (09) : 2500 - 2504
  • [3] Ketopiperazine-based renin inhibitors. 4. SAR of C ring benzyl ethers.
    Powell, NA
    Clay, E
    Holsworth, DD
    Jalaie, M
    Bryant, J
    Ryan, M
    Li, TS
    Karsana, A
    Maiti, S
    Edmunds, JJ
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U957 - U957
  • [4] Discovery of novel non-peptidic ketopiperazine-based renin inhibitors
    Holsworth, DD
    Powell, NA
    Downing, DM
    Cai, C
    Cody, WL
    Ryan, JM
    Ostroski, R
    Jalaie, M
    Bryant, JW
    Edmunds, JJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (07) : 2657 - 2664
  • [5] Ketopiperazine-based renin inhibitors - 2. Optimization of the "C" ring.
    Powell, NA
    Holsworth, DD
    Cody, WL
    Cheng, XM
    Lee, C
    Erasga, N
    Downing, DM
    Cai, CM
    Clay, E
    Jalaie, M
    Zhang, EL
    Bryant, J
    Ryan, M
    Edmunds, JJ
    Li, TS
    Kasani, A
    Hai, E
    Subedi, R
    Rahim, M
    Maiti, S
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U956 - U956
  • [6] Ketopiperazine-based renin inhibitors: Optimization of the "C" ring: Incorporation of indole rings
    Cai, Cuiman
    Bryant, John
    Cheng, Xue Min
    Cody, Wayne L.
    Collard, Wendy
    Downing, Dennis M.
    Erasga, Noe
    Ferreira, Suzie
    Hall, Eric
    Holsworth, Daniel D.
    Jalaie, Mehran
    Kasani, Aparna
    Lee, Chitase
    Li, Tingsheng
    Maiti, Samarendra
    McConnell, Patrick
    Powell, Noel A.
    Rahim, Mohammad
    Ryan, Michael
    Stier, Michael A.
    Subedi, Rajandra
    Zhang, Erli
    Edmunds, Jeremy J.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [7] Quantitative Structure-Activity Relationships of Renin Inhibitors
    Gupta, Satya P.
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2003, 3 (04) : 315 - 321
  • [8] Ketopiperazine-based renin inhibitors. 3. The S-enantiomer is also active.
    Powell, NA
    Clay, E
    Ciske, FL
    Holsworth, DD
    Lee, C
    Jalaie, M
    Bryant, J
    Ryan, M
    Edmunds, JJ
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U957 - U957
  • [9] Structure- and Ligand-Based Structure-Activity Relationships for a Series of Inhibitors of Aldolase
    Ferreira, Leonardo G.
    Andricopulo, Adriano D.
    [J]. CURRENT COMPUTER-AIDED DRUG DESIGN, 2012, 8 (04) : 309 - 316
  • [10] STRUCTURE-ACTIVITY RELATIONSHIPS FOR BENZYL ALCOHOLS
    TINLAND, B
    [J]. RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1973, 5 (03): : 855 - 857